Clinical study and prognosis analysis of Shenfu injection combined with ulinastatin in the adjuvant treatment of septic shock
Objective To explore the clinical effect of Shenfu injection combined with ulinastatin in the adjuvant treatment of septic shock.Methods Ninety-one patients with septic shock treated in Handan Central Hospital from January 2022 to June 2023 were selected as the study objects,and were divided into treatment group(47 cases)and control group(44 cases)according to random number table method.Both groups were given conventional treatment,the control group was given ulinastatin injection,and the treatment group was given Shenfu injection combined with ulinastatin injection.The levels of superoxide dismutase(SOD),malondialdehyde(MDA),nitric oxide(NO),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)before treatment and 1,3 and 7 days after treatment,as well as the time of admission to emergency intensive care unit(EICU)and 28 days mortality were compared between two groups.Results The duration of EICU stay in treatment group was significantly shorter than that in control group,and the 28 days mortality was significantly lower than that in control group(P＜0.05).After 1,3 and 7 days of treatment,the serum levels of TNF-α,IL-6,MDA and NO in two groups were significantly lower than before treatment,the SOD level in treatment group was significantly higher than before treatment,and the SOD level in control group first decreased and then increased(P＜0.05).The serum levels of TNF-α,IL-6,MDA and NO in treatment group were significantly lower than those in control group,and the level of SOD was significantly higher than that in control group(P＜0.05).Conclusion On the basis of conventional treatment,Shenfu injection combined with ulinastatin can further inhibit the release of inflammatory factors,reduce the level of oxidative stress,shorten the time of patients staying in EICU,reduce the 28d mortality,and provide a new idea for the treatment of septic shock.
国家科技期刊平台
NSTL
万方数据
